VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | Dose modification of ponatinib in CP-CML: data from the PACE and OPTIC trials

Elias Jabbour, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the feasibility of modifying the dose of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) to decrease the incidence of vascular events, highlighting data from the PACE (NCT01207440) and OPTIC (NCT02467270) trials. Overall, it was shown that adjusting drug dose based on response optimized treatment safety without compromising efficacy. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter